Primary mucinous cystadenocarcinoma of the breast: A case report and literature review

被引:1
作者
Cao, Xi [1 ]
Luo, Yongchao [1 ]
Shen, Songjie [1 ]
Ren, Xinyu [2 ]
机构
[1] Peking Union Med Coll & Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Breast Surg, Beijing 100730, Peoples R China
[2] Peking Union Med Coll & Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Pathol, Beijing 100730, Peoples R China
关键词
mucinous cystadenocarcinoma; breast; genomic profiling; follow-up; EXPRESSION; TUMOR; CARCINOMA; MUTATIONS; PROTEIN; MUC5AC; MUC2;
D O I
10.3892/ol.2024.14806
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Mucinous cystadenocarcinoma (MCA) is a rare breast cancer. The present study reports a case of primary MCA of the breast with a comprehensive evaluation of this rare tumour. A 51-year-old woman sought medical attention for a mass in the left breast. A core needle biopsy revealed an infiltrating adenocarcinoma with mucus secretion and papillary formation. The macroscopic appearance was of a greyish-white, tough and well-circumscribed solid mass, without a notable cyst. Microscopically, the tumour consisted of ducts and cysts of varying sizes. Varying degrees of branching papillary structures were observed in the lumen and cyst cavities. The tumour cells were highly columnar in shape, with high-grade nuclei arranged in a single-layer. Immunohistochemistry revealed that the tumour was a basal-like triple-negative breast cancer with a high proliferation index and tumour protein p53 diffuse strong expression. Mutations in breast cancer 1-associated RING domain 1 (BARD1), kinase domain containing receptor (KDR), mucin-6 (MUC6), tumour protein 53 (TP53) and breast cancer 1-interacting protein C-terminal helicase 1 (BRIP1) were identified using DNA analysis. The patient was followed up for 26 months and showed no signs of recurrence or metastasis. In conclusion, the current study presents a case of MCA of breast accompanied by mutations in the BARD1, KDR, MUC6, TP53 and BRIP1 genes, with no recurrence after a 26-month follow-up. Combining this case with a review of the literature helps us to better understand the clinicopathological and genetic characteristics of MCA, and guide treatment.
引用
收藏
页数:9
相关论文
共 55 条
[1]   The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging [J].
Amin, Mahul B. ;
Greene, Frederick L. ;
Edge, Stephen B. ;
Compton, Carolyn C. ;
Gershenwald, Jeffrey E. ;
Brookland, Robert K. ;
Meyer, Laura ;
Gress, Donna M. ;
Byrd, David R. ;
Winchester, David P. .
CA-A CANCER JOURNAL FOR CLINICIANS, 2017, 67 (02) :93-99
[2]   Molecular Analysis of Renal/Adrenal Angiosarcomas Reveals High Frequency of Recurrent Genetic Alterations [J].
Argani, Pedram ;
Saoud, Carla ;
Antonescu, Cristina R. .
GENES CHROMOSOMES & CANCER, 2024, 63 (09)
[3]   Characterizing and forecasting neoantigens-resulting from MUC mutations in COAD [J].
Chen, Min ;
Zhang, Xin ;
Ming, Zihe ;
Lingyu ;
Feng, Xiaorong ;
Han, Zhenguo ;
An, Han-Xiang .
JOURNAL OF TRANSLATIONAL MEDICINE, 2024, 22 (01)
[4]  
Chen Shujie, 2021, J BUON, V26, P1991
[5]   Mucinous cystadenocarcinoma of the breast coexisting with infiltrating ductal carcinoma [J].
Chen, WY ;
Chen, CS ;
Chen, HC ;
Hung, YJ ;
Chu, JS .
PATHOLOGY INTERNATIONAL, 2004, 54 (10) :781-786
[6]   Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples [J].
Cibulskis, Kristian ;
Lawrence, Michael S. ;
Carter, Scott L. ;
Sivachenko, Andrey ;
Jaffe, David ;
Sougnez, Carrie ;
Gabriel, Stacey ;
Meyerson, Matthew ;
Lander, Eric S. ;
Getz, Gad .
NATURE BIOTECHNOLOGY, 2013, 31 (03) :213-219
[7]   Mammary mucinous cystadenocarcinoma [J].
Coyne, J. D. ;
Irion, L. .
HISTOPATHOLOGY, 2006, 49 (06) :659-660
[8]   Mucinous cystadenocarcinoma of the breast with a basal-like immunophenotype [J].
Deng, Yunte ;
Xue, Debin ;
Wang, Xiaoyan ;
Xu, Sanpeng ;
Ao, Qilin ;
Hu, Zhiyong ;
Wang, Guoping .
PATHOLOGY INTERNATIONAL, 2012, 62 (06) :429-432
[9]   Mucinous cystadenocarcinoma of the breast showing sulfomucin production [J].
Domoto, H ;
Terahata, S ;
Yamazaki, T ;
Sato, K ;
Takeo, H ;
Tamai, S .
HISTOPATHOLOGY, 2000, 36 (06) :567-569
[10]  
Dorling L., 2021, NEW ENGL J MED, V384, P428, DOI [10.1056/NEJMoa1913948, DOI 10.1056/NEJMOA1913948]